User:Mr. Ibrahem/Flotufolastat F-18

Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent used in positron emission tomography (PET) imaging of prostate cancer. Specifically it is used in prostate-specific membrane antigen (PSMA) positive disease to look for spread or recurrence. It is given by injection into a vein.

Common side effects include diarrhea, high blood pressure, and pain at the site of injection. Other side effects include exposure to radiation. The active ingredient is flotufolastat F-18 gallium.

Flotufolastat F-18 was approved for medical use in the United States in 2023.